Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4.

Autor: van Sonderen A; Department of Neurology, Erasmus University Medical Center, Rotterdam.; Department of Neurology, Haga Hospital, the Hague., Roelen DL; Department of Immunogenetics and Transplantation Immunology, Leiden University Medical Center, Leiden., Stoop JA; Department of Pathology, Erasmus University Medical Center, Rotterdam., Verdijk RM; Department of Pathology, Erasmus University Medical Center, Rotterdam., Haasnoot GW; Department of Immunogenetics and Transplantation Immunology, Leiden University Medical Center, Leiden., Thijs RD; Foundation Epilepsy Institutes Netherlands, Heemstede.; Department of Neurology, Leiden University Medical Center, Leiden., Wirtz PW; Department of Neurology, Haga Hospital, the Hague., Schreurs MW; Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands., Claas FH; Department of Immunogenetics and Transplantation Immunology, Leiden University Medical Center, Leiden., Sillevis Smitt PA; Department of Neurology, Erasmus University Medical Center, Rotterdam., Titulaer MJ; Department of Neurology, Erasmus University Medical Center, Rotterdam.
Jazyk: angličtina
Zdroj: Annals of neurology [Ann Neurol] 2017 Feb; Vol. 81 (2), pp. 193-198. Date of Electronic Publication: 2017 Jan 27.
DOI: 10.1002/ana.24858
Abstrakt: Leucine-rich glioma-inactivated1 (LGI1) encephalitis is an antibody-associated inflammation of the limbic area. An autoimmune etiology is suspected but not yet proven. We performed human leukocyte antigen (HLA) analysis in 25 nontumor anti-LGI1 patients and discovered a remarkably strong HLA association. HLA-DR7 was present in 88% compared to 19.6% in healthy controls (p = 4.1 × 10 -11 ). HLA-DRB4 was present in all patients and in 46.5% controls (p = 1.19 × 10 -7 ). These findings support the autoimmune hypothesis. An exploratory analysis was performed in a small group of 4 tumor-LGI1 patients. The strong HLA association seems not applicable in these patients. Therefore, the absence of HLA-DR7 or HLA-DRB4 could raise tumor suspicion in anti-LGI1 patients. Ann Neurol 2017;81:193-198.
(© 2016 American Neurological Association.)
Databáze: MEDLINE
Externí odkaz: